Page last updated: 2024-09-05

sb 203580 and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid

sb 203580 has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 2 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies ((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid)	Trials ((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid)	Recent Studies (post-2010) ((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid)
3,489	4	1,137	1,459	368	396

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dawson, KA; Gallagher, WM; Hickey, JA; Keenan, AK; McGillicuddy, FC; O'Toole, D	1
Maruyama, K; Morishita, E; Ohtake, S; Sekiya, A; Torishima, H	1

Other Studies

2 other study(ies) available for sb 203580 and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid

Article	Year
TGF-beta1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells. Vascular pharmacology, 2006, Volume: 44, Issue:6 Topics: Adult; Cells, Cultured; Coronary Restenosis; Coronary Vessels; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Indoles; Male; MAP Kinase Signaling System; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; RNA, Messenger; Thrombospondin 1; Transforming Growth Factor beta; Transforming Growth Factor beta1	2006
Fluvastatin Upregulates the Expression of Tissue Factor Pathway Inhibitor in Human Umbilical Vein Endothelial Cells. Journal of atherosclerosis and thrombosis, 2015, Jul-23, Volume: 22, Issue:7 Topics: Anticoagulants; Antigens; Blotting, Western; Cells, Cultured; Chromones; Dactinomycin; Fatty Acids, Monounsaturated; Fluvastatin; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Indoles; Lipoproteins; Luciferases; Maleimides; Mevalonic Acid; Morpholines; Pyridines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Up-Regulation	2015

Article

Year

TGF-beta1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells.

Vascular pharmacology, 2006, Volume: 44, Issue:6

Topics: Adult; Cells, Cultured; Coronary Restenosis; Coronary Vessels; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Indoles; Male; MAP Kinase Signaling System; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; RNA, Messenger; Thrombospondin 1; Transforming Growth Factor beta; Transforming Growth Factor beta1

2006

Fluvastatin Upregulates the Expression of Tissue Factor Pathway Inhibitor in Human Umbilical Vein Endothelial Cells.

Journal of atherosclerosis and thrombosis, 2015, Jul-23, Volume: 22, Issue:7

Topics: Anticoagulants; Antigens; Blotting, Western; Cells, Cultured; Chromones; Dactinomycin; Fatty Acids, Monounsaturated; Fluvastatin; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Indoles; Lipoproteins; Luciferases; Maleimides; Mevalonic Acid; Morpholines; Pyridines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Up-Regulation

2015